US EPA has accepted our studies including EDSP Tier-I, DART, Immunotoxicity and Neurotoxicity studies
As part of a recent regulatory submission (June 2015) a number of JRF studies were reviewed and classified as 'Acceptable: - Guideline' by US EPA.
The US EPA issued Draft Human Health Risk Assessment for a certain product in June 2015, accepting our studies for DART, Immunotox and Neurotox evaluations for the said product. Needless to mention, all these studies are challenging, driven by strong activity scheduling skills. The need for strong historical control data makes these studies quite challenging. JRF's strength in the above areas ensures smooth passage of the studies at the regulator's office.
This is an illustrious achievement for the JRF team, which speaks volumes about their scientific acumen under the GLP environment, specific study related expertise as well as our internal project management systems and processes. The global experts in this field have appreciated the extent of forward planning necessary for undertaking the DART studies. With this, we have three major DART studies including extended-one-generation studies, well received by the US EPA regulator in a span of three years. Strong science, guideline and GLP compliance and computerized data capture processes ensure clean and fool-proof data generation. These processes, in turn, ensure regulatory acceptance.
This adds further experience with US EPA regulatory submissions to JRF's non-clinical portfolio building on a number of previous US EPA submissions over the past three years.
"We are delighted with the approval and acceptance of our client's study data" said Dr. Abhay Deshpande, Director Global - JRF. "We are proud to offer our scientific contributions to non-clinical services globally. We strongly believe these positive achievements position us as a global CRO with strong and reliable scientific, quality and project management capabilities for our global clients”.
JRF Global is a multinational Contract Research Organization, established in 1977 with an extensive portfolio of non-clinical regulatory research services. We serve our global client base by offering high quality GLP reports and ensuring rapid turnaround time, on-time delivery and constant communication and updates. Recently, JRF Global has strategically diversified to several specialized services, which include;
- Endocrine Disruptor Screening (discovery as well as regulatory in compliance with the global guidelines),
- Several in vitro (Alternative Testing) regulatory as well as discovery research driven services,
- Zebra fish Research (discovery support as well as guideline compliant studies).
For more information, please visit at www.jrfglobal.com
JRF Business Development Team
Contact: +1 (877) 937 5732